- Home
- GNTA vs LPTX Comparison
GNTA vs LPTX Comparison
Compare GNTA & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNTA
- LPTX
- Stock Information
- Founded
- GNTA 2014
- LPTX 2011
- Country
- GNTA Italy
- LPTX United States
- Employees
- GNTA N/A
- LPTX N/A
- Industry
- GNTA Biotechnology: Biological Products (No Diagnostic Substances)
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GNTA Health Care
- LPTX Health Care
- Exchange
- GNTA Nasdaq
- LPTX Nasdaq
- Market Cap
- GNTA 96.0M
- LPTX 108.4M
- IPO Year
- GNTA 2021
- LPTX N/A
- Fundamental
- Price
- GNTA $5.01
- LPTX $2.91
- Analyst Decision
- GNTA Strong Buy
- LPTX Strong Buy
- Analyst Count
- GNTA 1
- LPTX 3
- Target Price
- GNTA $25.00
- LPTX $7.50
- AVG Volume (30 Days)
- GNTA 5.8K
- LPTX 455.1K
- Earning Date
- GNTA 01-01-0001
- LPTX 11-13-2024
- Dividend Yield
- GNTA N/A
- LPTX N/A
- EPS Growth
- GNTA N/A
- LPTX N/A
- EPS
- GNTA N/A
- LPTX N/A
- Revenue
- GNTA N/A
- LPTX N/A
- Revenue This Year
- GNTA N/A
- LPTX N/A
- Revenue Next Year
- GNTA N/A
- LPTX N/A
- P/E Ratio
- GNTA N/A
- LPTX N/A
- Revenue Growth
- GNTA N/A
- LPTX N/A
- 52 Week Low
- GNTA $2.20
- LPTX $1.68
- 52 Week High
- GNTA $7.28
- LPTX $5.00
- Technical
- Relative Strength Index (RSI)
- GNTA 47.05
- LPTX 47.52
- Support Level
- GNTA $4.95
- LPTX $2.75
- Resistance Level
- GNTA $5.50
- LPTX $3.12
- Average True Range (ATR)
- GNTA 0.27
- LPTX 0.31
- MACD
- GNTA -0.01
- LPTX -0.02
- Stochastic Oscillator
- GNTA 45.56
- LPTX 23.41
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain, and TEMs -Immuno-Gene Therapy.
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .